RSPH - ETF AI Analysis
Top Page
Invesco S&P 500 Equal Weight Health Care ETF (RSPH)
RSPH, the Invesco S&P 500 Equal Weight Health Care ETF, has a solid overall rating that reflects a portfolio of generally strong, established healthcare companies. High-quality holdings like Intuitive Surgical, Agilent, Thermo Fisher, and Illumina support the fund’s quality through robust financial performance, strategic growth initiatives, and positive earnings outlooks. The main risk is that many of these companies share similar challenges—especially high valuations, mixed technical signals, and some cash flow or leverage concerns—so the ETF is exposed to sector-wide valuation and profitability pressures within healthcare.
RSPH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 991.68M
- Region
- North America
- Expense Ratio
- 0.40%
- Beta
- 0.52
- Issuer
- Invesco
- Inception Date
- Nov 01, 2006
- Dividend Yield
- 0.56%
- Asset Class
- Equity
- Index Tracked
- S&P 500 Equal Weighted / Health Care -SEC
RSPH Summary
RSPH is the Invesco S&P 500 Equal Weight Health Care ETF, which follows an index of U.S. health care companies in the S&P 500 and gives each stock roughly the same weight. It includes a mix of drug makers, biotech firms, medical device companies, and health care service providers. Well-known names in the fund include Moderna and Intuitive Surgical. Investors might consider RSPH if they want diversified exposure to the growth and innovation of the health care sector without concentrating too much in the biggest companies. A key risk is that it is heavily focused on health care, so its value can rise or fall with that sector.
How much will it cost me?
This ETF has an expense ratio of 0.40%, which means you’ll pay about $4 per year for every $1,000 you invest. That’s a bit higher than the cheapest broad index ETFs because this fund uses a more specialized, equal-weight strategy focused on the health care sector.
What would affect this ETF?
This ETF is heavily focused on U.S. health care, so it could benefit from aging populations, medical innovation in areas like biotech and devices, and steady demand for services that support companies such as Moderna, Illumina, and Intuitive Surgical. On the downside, it is vulnerable to changes in health care regulation, drug pricing pressures, and broader market or economic downturns that could hurt the entire sector despite its diversified, equal-weight approach.
RSPH Top 10 Holdings
RSPH is a pure U.S. health care play, and its story right now is all about innovative tools and biotech. Lab and diagnostics names like Mettler-Toledo, Agilent, and Waters are steadily lifting the fund, helped by rising momentum in Charles River Labs and Revvity. On the biotech side, Moderna has been climbing again, giving the ETF a shot in the arm despite its choppy fundamentals. Intuitive Surgical, usually a star, has been more mixed and is losing a bit of steam, slightly dampening returns in an otherwise broadly rising health care lineup.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 MRNA | Moderna | 2.49% | $24.44M | $88.52B | 687.92% | 59Neutral |
 ILMN | Illumina | 1.76% | $17.22M | $35.63B | 138.35% | 71Outperform |
 CRL | Charles River Labs | 1.97% | $19.29M | $17.16B | 100.66% | 60Neutral |
 RVTY | Revvity | 1.93% | $18.94M | $17.52B | 72.49% | 67Neutral |
 MTD | Mettler-Toledo | 1.99% | $19.46M | $33.56B | 21.63% | 64Neutral |
 ISRG | Intuitive Surgical | 1.86% | $18.27M | $149.75B | -18.49% | 78Outperform |
 A | Agilent | 1.84% | $18.06M | $49.30B | 21.98% | 73Outperform |
 VEEV | Veeva Systems | 1.83% | $17.93M | $50.67B | 9.80% | 66Neutral |
 WST | West Pharmaceutical Services | 1.87% | $18.30M | $28.74B | 48.14% | 68Neutral |
 WAT | Waters | 1.74% | $17.09M | $45.46B | 34.94% | 70Outperform |
RSPH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RSPH, the sentiment is Positive. The current price of 39.69 is above the 20-day moving average (MA) of 38.63, above the 50-day MA of 37.70, and above the 200-day MA of 33.56, indicating a bullish trend. The MACD of 0.72 indicates Negative momentum. The RSI at 64.58 is Neutral, neither overbought nor oversold. The STOCH value of 75.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RSPH.
RSPH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| RSPH | $39.69 | $42.00(5.82% Upside) | $991.68M | 0.40% | 71Outperform |
 PJP | $130.54 | $158.86(21.69% Upside) | $575.09M | 0.58% | 70Neutral |
 XPH | $64.80 | $109.12(68.40% Upside) | $466.58M | 0.35% | 56Neutral |
 PINK | $40.62 | $50.39(24.04% Upside) | $335.60M | 0.51% | 65Neutral |
 PTH | $59.78 | $76.82(28.50% Upside) | $302.68M | 0.60% | 60Neutral |
 PSCH | $55.69 | $67.48(21.17% Upside) | $182.03M | 0.29% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 39.69 | 9.65 | 32.11% | |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 130.54 | 34.57 | 36.02% | |
| XPH | SPDR S&P Pharmaceuticals ETF | 64.80 | 15.34 | 31.00% | |
| PINK | Simplify Health Care ETF | 40.62 | 7.99 | 24.47% | |
| PTH | Invesco DWA Healthcare Momentum ETF | 59.78 | 13.14 | 28.17% | |
| PSCH | Invesco S&P SmallCap Health Care ETF | 55.69 | 13.32 | 31.44% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.